Analysts have been eager to weigh in on the Healthcare sector with new ratings on Charles River Labs (CRL – Research Report) and Stryker (SYK – Research Report).
Charles River Labs (CRL)
In a report released yesterday, John Sourbeer from UBS maintained a Buy rating on Charles River Labs, with a price target of $215.00. The company’s shares closed last Thursday at $169.47, close to its 52-week low of $161.65.
According to TipRanks.com, Sourbeer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Charles River Labs has an analyst consensus of Moderate Buy, with a price target consensus of $202.41, which is a 14.2% upside from current levels. In a report issued on November 8, Evercore ISI also maintained a Buy rating on the stock with a $190.00 price target.
See the top stocks recommended by analysts >>
Stryker (SYK)
UBS analyst Danielle Antalffy maintained a Hold rating on Stryker yesterday and set a price target of $297.00. The company’s shares closed last Thursday at $270.84.
According to TipRanks.com, Antalffy is a 4-star analyst with an average return of
Currently, the analyst consensus on Stryker is a Moderate Buy with an average price target of $322.56, a 16.7% upside from current levels. In a report issued on November 3, Needham also maintained a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRL:
